article thumbnail

How Japan and South Korea are Shaping the Next Era of Clinical Development

Fierce BioTech

How Japan and South Korea are Shaping the Next Era of Clinical Development Discover why Japan and South Korea are emerging as clinical trial powerhouses, offering cutting-edge infrastructure, streamlined regulations, and unique commercial advantages. CMIC Group Resource Type Whitepaper CMIC_ListingLogo_250x190.png

article thumbnail

Getting the Pulse on Biopharma and Biotech Companies: Differing Perspectives on Clinical Development

PPD

To keep a pulse on this rapidly changing industry, the PPD clinical research business of Thermo Fisher Scientific surveyed 150 leaders in the biopharma and biotech industries for the second consecutive year. Differences in size, resources and agility have led the two groups to take different approaches to clinical development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FSP Engagements Continue to Gain Popularity, Drive Success

PPD

A large majority of drug developers utilize FSP or hybrid FSP/FSO models, half are “heavy users” Heavy users: Those that use FSP or hybrid FSP/FSO models for most of their clinical development outsourcing. Heavy users leverage these models for nearly three-quarters of their outsourcing.

article thumbnail

Beyond the Lab: Cell & Gene Therapy

Drug Target Review

Please click download to access this FREE resource. This report offers an unparalleled opportunity to explore the forefront of drug discovery and gain valuable insights from industry leaders and experts.

article thumbnail

Powering Regulatory Strategy With Artificial Intelligence: How to Streamline Strategic Processes and Accelerate Approval

Fierce BioTech

jsabatino Tue, 10/10/2023 - 09:03 Download now to explore this challenge in detail, explaining the difficulties faced by regulatory affairs leaders and how regulatory intelligence solutions powered by artificial intelligence offer a path to enhancing efficiency and accelerating approvals.

article thumbnail

Ascentage Pharma’s Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment

The Pharma Data

UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases. This progress in clinical development qualifies Ascentage Pharma for a milestone payment according to the terms of the licensing agreement. SUZHOU, China and ROCKVILLE, Md. ,

article thumbnail

Reimagining CRO Partnerships: The Emerging Preference for Midsize Organizations

Conversations in Drug Development Trends

To gain deeper insights into this pivotal shift and how it can benefit your clinical development strategy, we invite you to download our full industry survey report. This industry shift represents not just a change in sponsor preference but rather a broader reevaluation of what attributes are most valued in a CRO partnership.